Qili Qiangxin capsules——effective in treating chronic heart failure

[Functions and Indications] To tonify qi, warm yang, activate blood, unblock the collaterals, promote urination and alleviate edema. Mild and moderate congestive heart failure of yang qi deficiency, obstruction of collaterals and water retention manifested as palpitations and shortness of breath worsening upon physical movement, difficulty in lying down, edema in the lower limbs, fatigue, lack of strength, scanty urine, cyanotic mouth and lips, fear of cold with cold limbs, and expectoration of thin white sputum; Coronary heart disease and hypertension with the symptoms described above.
[Main Ingredients] Astragali Radix, Ginseng Radix et Rhizoma, Aconiti Lateralis Radix Preparata, Salvia miltiorrhiza Radix et Rhizoma,Descurainiae Semen lepidii Semen, Alismatis Rhizoma, Polygonati Odorati Rhizoma, Cinnamomi Ramulus, Carthami Flos,
Periplocae Cortex, Citri Reticulatae Pericarpium.
[Dosage] Take orally, 4 capsules/time, 3 times/day.
[Specification] 0.3g/capsule.
[Packing] Blister package, 36 capsules/box, 400boxes/carton.
[MA Number] License of State Drug Administration Z20040141.

Heart failure is the ultimate cause of death for all kinds of heart diseases in the late stage. Few great breakthroughs have been obtained over the past two decades, and the research and development of effective drugs for the treatment of heart failure is still a major topic in the international medical community. Researched and developed under the guidance of Collateral Disease Theory, Qili Qiangxin Capsule has been widely researched to compare with western medicine and the results have showed that it has the comprehensive effects of first-line and second-line western medicines, and also the unique advantages by reducing myocardial cell apoptosis and improving energy metabolism.

● It has similar cardiotonic effect to Digoxins.
● It has better effect to reduce kidney aquaporin-2 than Furosemide.
● It has better effect to inhibit AngII than Ramipril.
● It has better effect to inhibit ventricular remodeling than Metoprolol.
● Reduce the apoptosis and autophagy of cardiomyocytes
● Promote cardiomyocyte proliferation
● Improve myocardial energy metabolism
● Treat arrhythmia

A new patent drug for treating chronic heart failure in terms of both symptoms and root causes——Qili Qiangxin capsules
The only innovative TCM medicine proved by clinical evidence-based medicine to treat chronic heart failure
The only innovative TCM medicine recognized by the international authoritative journal for effective treatment of chronic heart failure
The only innovative TCM medicine included in the Guidelines for Diagnosis and Treatment of Heart Failure by the Chinese Medical Association (CMA)

● National Varieties for Medical Insurance Drugs
● National Key New Product designated by the Ministry of Science and Technology of the P.R.C.
● National Key New Product
● Projected funded by the National 863 Program of the Ministry of Science and Technology
● Projected supported by the “11th-Five Year Plan”
● High-tech Industrialization Demonstration Project designated by the National Development and Reform Commission (NDRC)

Qili Qiangxin Capsule, successfully developed by the National 863 Program, has brought a new hope for the drug treatment of patients with chronic heart failure. The clinical evidence-based research paper published in the Journal of the American College of Cardiology (JACC) is the most influential SCI paper in terms of the clinical research on TCM medicines. Extensive experimental studies have revealed the pharmacodynamic mechanism of Qili Qiangxin Capsule. The high attention of the international medical community has showed the important clinical value and broad market prospect of this drug in the treatment of chronic heart failure.